Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Lambert Potin"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ca74518ccd6a4cf5991db1b2af8229fd
Autor:
Aymeric Auger, Laura Santambrogio, Patricia Corthésy, Davide Demurtas, Emanuela Romano, Melody A. Swartz, Lambert Potin, Maurice Matter, Cristina C. Clement, Romain Hamelin, Alexandre Harari, Daniel E. Speiser, Natacha Bordry, Lea Maillat, Maria A. S. Broggi
Publikováno v:
The Journal of Experimental Medicine
The Journal of experimental medicine, vol. 216, no. 5, pp. 1091-1107
The Journal of experimental medicine, vol. 216, no. 5, pp. 1091-1107
Identifying cancer biomarkers is of great interest for patient prognosis and monitoring. However, tumor-associated factors are diluted in blood and challenging to detect. Broggi et al. show that lymphatic exudate, accessible at the time of lymphadene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18f6806c0790a1e5f776aeca52a5a9a1
http://europepmc.org/articles/PMC6504224
http://europepmc.org/articles/PMC6504224
Autor:
Tiffany M. Marchell, Ako Ishihara, Michal M. Raczy, Jun Ishihara, Jeffrey A. Hubbell, Peyman Hosseinchi, Aslan Mansurov, Melody A. Swartz, Aaron T. Alpar, Laura T. Gray, Lambert Potin, John-Michael Williford
Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in 'immunologically cold' tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive arms of the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faad1582775a7a1e09db5a5eac713d07
http://hdl.handle.net/10044/1/83774
http://hdl.handle.net/10044/1/83774
Autor:
Tiffany M. Marchell, Melody A. Swartz, Ako Ishihara, Jun Ishihara, Aslan Mansurov, Jeffrey A. Hubbell, Peyman Hosseinchi, Lambert Potin, John-Michael Williford
Publikováno v:
Science Advances
Targeted delivery of CCL4 to the tumor stroma recruits CD103+ dendritic cells and enhances the efficacy of CPI immunotherapy.
Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inh
Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f306b9ac7c8c2d01998b80fbeb6fe59e
https://doi.org/10.1126/sciadv.aay1357
https://doi.org/10.1126/sciadv.aay1357
Autor:
Gavin Fujimori, Aslan Mansurov, Jeffrey A. Hubbell, Melody A. Swartz, Peyman Hosseinchi, Lambert Potin, Lea Maillat
Publikováno v:
Cancer Research. 80:5695-5695
Growth and remodeling of tumor-associated lymphatics, termed lymphangiogenesis, has been known to increase metastasis rate in cancer patients. However, a recent study from our group has shown that tumor-associated lymphatics can improve anti-tumor im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fec84d786f35613fe52ec6d21f0fa18b
https://doi.org/10.1158/1538-7445.am2020-5695
https://doi.org/10.1158/1538-7445.am2020-5695
Autor:
Jeffrey A. Hubbell, Lea Maillat, Lambert Potin, Peyman Hosseinchi, Melody A. Swartz, Aslan Mansurov
Publikováno v:
Cancer Immunology Research. 8:B97-B97
During cancer development, growth and remodeling of lymphatic vessels—termed lymphangiogenesis—is associated with increased metastasis rate. However, our group has recently shown that lymphangiogenesis can also increase tumor immune infiltration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c931762b96268db0f97285c8c7f6d6e5
https://doi.org/10.1158/2326-6074.tumimm19-b97
https://doi.org/10.1158/2326-6074.tumimm19-b97
Autor:
Cara L. Hrusch, Harri Nurmi, Katharina Maisel, Daniel F. Camacho, Rachel Gleyzer, Anne I. Sperling, David B. Chapel, Kari Alitalo, Jorge Emiliano Gomez Medellin, Lambert Potin, Melody A. Swartz
Publikováno v:
Mucosal immunology
In allergic airway inflammation, VEGFR-3-mediated lymphangiogenesis occurs in humans and mouse models, yet its immunological roles, particularly in adaptive immunity, are poorly understood. Here, we explored how pro-lymphangiogenic signaling affects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa00d15c63efd85da41e8aec2e38de4
https://pubmed.ncbi.nlm.nih.gov/32518367
https://pubmed.ncbi.nlm.nih.gov/32518367
Autor:
Aslan, Mansurov, Jun, Ishihara, Peyman, Hosseinchi, Lambert, Potin, Tiffany M, Marchell, Ako, Ishihara, John-Michael, Williford, Aaron T, Alpar, Michal M, Raczy, Laura T, Gray, Melody A, Swartz, Jeffrey A, Hubbell
Publikováno v:
Nature biomedical engineering. 4(5)
Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in 'immunologically cold' tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive arms of the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1e0593f3a2c86b8f4e8c09c727d15ac2
https://pubmed.ncbi.nlm.nih.gov/32409704
https://pubmed.ncbi.nlm.nih.gov/32409704
Autor:
John-Michael Williford, Koichi Sasaki, Melody A. Swartz, Michal M. Raczy, Laura T. Gray, Hiroyuki Abe, Peyman Hosseinchi, Mariko Yasui, Steve S. Lee, Jeffrey A. Hubbell, Kiyomitsu Katsumata, Aslan Mansurov, Ako Ishihara, Lambert Potin, Stephen J. Kron, Masashi Fukayama, Jun Ishihara, Kazuto Fukunaga
Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2da2d838c5c4b7788b32d5e26d9fd60
https://europepmc.org/articles/PMC6541444/
https://europepmc.org/articles/PMC6541444/
Publikováno v:
Cancer Research. 79:4520-4520
Prior to metastasis, tumor-draining lymph nodes and distant organs are altered by a number of tumor-derived factors that help to both suppress host immunity as well as form an environment that supports metastatic tumor cells, i.e., a pre-metastatic n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd3f5dd4378c601e9a628e8f22b21a2c
https://doi.org/10.1158/1538-7445.am2019-4520
https://doi.org/10.1158/1538-7445.am2019-4520